Virginia’s Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting
600 East Broad Street – 7th Floor Conference Rooms
Richmond, Virginia 23219
Thursday, September 17, 2020 - 10:00 a.m.

Please click on this link to join the WebEx
Audio Access: 866-692-4530; Pin 161 535 7780

This is an electronic public meeting held pursuant to Items 4-0.01(g) in House Bill 29 and House Bill 30.
The FOIA Councils “Electronic Meetings Public Comment” form for submitting feedback on this electronic meeting may be accessed at http://foiacouncil.dls.virginia.gov/sample%20letters/welcome.htm

Welcome and Comments from DMAS’ Director
Karen Kimsey

Call to Order
Chethan Bachireddy, MD, CMO, Chair

Approval of Minutes from April 20, 2020 Meeting
P&T Committee Members

Drug Utilization Review (DUR) Board Update
Rachel Cain, PharmD

PDL Management
P&T Committee Members

PDL Phase II – New Drug Review (Therapeutic Class)

Brand Drugs
- Arazlo® (Acne Agents, Topical)
- Avsola™ (Cytokine & Cam Antagonists) (Closed class)
- Licart Patch (Topical NSAIDS)
- Lyumjev™ (Hypoglycemics, Insulin & Related Agents)
- Nurtec® ODT (Antimigraine Agents, Other)
- Trijardy® XR (Hypoglycemics, SGLT2) (Closed class)
- Zeposia® (Multiple Sclerosis Agents)
- Zilxi™ Foam (Rosacea Agents, Topical)

Generics Drugs and New Dosage Forms
- TBA

PDL Phase I – Annual Review

Antibiotics/Anti-Infectives
- Antibiotics, Vaginal

Antivirals
- Hepatitis C Agents (Closed Class)

Blood Modifiers
- Bile Salts
- Phosphate Binders

Cardiac Medications
- Angiotensin Modulators (includes ACEs, ARBs, & CCB combination products)
- Angiotensin Modulators II (includes Direct Renin Inhibitors & combination products)
- Antihypertensives, Sympatholytics (Closed Class)
Cardiac Medications (cont)
- Beta Blockers (includes combination products)
- Calcium Channel Blockers (includes dihydropyridine and non-dihydropyridine agents)
- Lipotropics, Other (includes Bile Acid Sequestrants, Cholesterol Absorption Inhibitor agents, Fibric Acid derivatives, Microsomal Triglyceride Transfer Protein Inhibitors, Niacin derivatives, Oligonucleotide Inhibitors and Omega 3 agents)
- Lipotropics, Statins
- Pulmonary Arterial Hypertension Agents, Oral/Inhaled/Injectable (includes Endothelin-1 agents, PDE-5 Inhibitors; Prostacyclin analogues, Prostacyclin Vasodilator, Soluble Guanylate Cyclase Stimulators)

Central Nervous System
- Anticonvulsants
- Alzheimer’s Agents
- Antidepressants, SSRI
- Antidepressants, Other
- Antipsychotics (includes oral and long-acting injectables) (Closed Class – LA injectables only)
- Sedative Hypnotics

Dermatitis
- Immunomodulators, Atopic Dermatitis
- Steroids, Topical

Endocrine & Metabolic Agents
- Glucocorticoids, Oral
- Growth Hormones (Closed Class)
- Hereditary Angioedema (HAE)
- Progestins for Cachexia

Gastrointestinal
- Antiemetic/Antivertigo Agents
- GI Motility, Chronic
- H. pylori Agents
- Histamine-2 Receptor Antagonists (H-2RA)
- Proton Pump Inhibitors
- Ulcerative Colitis

Genitourinary
- BPH Agents (includes Alpha Blockers, Androgen Hormone Inhibitors and Phosphodiesterase (PDE) 5 Inhibitors for BPH treatment)
- Bladder Relaxants

Ophthalmics
- Allergic Conjunctivitis (includes Ophthalmic Antihistamines & Mast Cell Stabilizers)
- Antibiotics
- Antibiotic/Steroid Combinations
- Anti-Inflammatory Agents (includes Ophthalmic NSAIDS & Corticosteroids)
- Glaucoma Agents (includes Alpha-2 Adrenergics, Beta-blockers, Carbonic Anhydrase Inhibitors, Prostaglandin Inhibitors)

Respiratory
- Anti-Allergens, Oral
- Antibiotics, Inhaled (Closed Class)
- Antihistamines Minimally Sedating
- Bronchodilators, Long Acting Beta Adrenergics
- Bronchodilators, Short Acting Beta Adrenergics
Respiratory (cont)
- Cough & Cold Agents (Legend)
- COPD (includes Anticholinergics, Bronchodilators and Phosphodiesterase 4 (PDE4) Inhibitors) (Closed Class)
- Epinephrine, Self-Injected
- Glucocorticoids (includes nebulized solutions, metered dose inhalers and combinations) (Closed Class)
- Intranasal Rhinitis (includes Antihistamines and Corticosteroids)
- Leukotriene Modifiers

Confidential Meeting (Pricing Information Discussion)

P&T Committee, DMAS & MMA Staff
Pursuant to 42 USC §1396r-8

PDL Recommendations and Vote

P&T Committee Members

Criteria Discussion of Phase II New Drugs*

P&T Committee Members

Criteria Discussion of PDL Phase I Drug Classes*

P&T Committee Members

Next Meeting - tentatively scheduled for March 18, 2021

*Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.

Oral Presentations: The P&T Committee in conjunction with the Department will allocate a maximum of thirty (30) minutes for interested parties to present scientific and clinical information on PDL Phase I drugs in classes which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve no more than fifteen (15) presentation requests based on relevancy of the information. Speakers must receive a confirmation number to verify the presentation is scheduled.

All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:

- PDL Phase I Annual Reviews – September 2019 to present
- New Drugs in PDL Phase I or II Drug Classes – September 2018 to present

No anecdotal accounts are to be given.

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Approved speakers must provide their email address to the Department and will be required to register for the WebEx on the day of the meeting. Please send requested information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on Monday, August 17, 2020.

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov by 5 p.m. EST on Monday, August 17, 2020.